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We would like to provide a clarification to the
reader about our article ‘‘Efficacy and Treatment
Costs of Monotherapy with bDMARDs in the
Treatment of Rheumatoid Arthritis in Patients
Intolerant to or Inappropriate to Continue
Treatment with Methotrexate’’ published in
issue 33, pp 1360–1373.
In Italy tocilizumab adheres to the payback
system, so its ex-factory price does not include
the ex-ante discount of 5%, differently from
adalimumab and etanercept. The detail of the
ex-post economic compensation for
tocilizumab is not publicly available so we
could not take it into account. Therefore, for
all the drugs considered in the analysis, for
comparability purpose only the temporary
discount of -5% imposed by national law is
taken into consideration.
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